A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

699

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Obesity
Interventions
DRUG

CP-945,598

CP-945,598

BEHAVIORAL

Non-pharmacological weight loss program (NPP)

Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.

BEHAVIORAL

Low Calorie Diet

Low calorie diet

Trial Locations (26)

1958

Pfizer Investigational Site, Frederiksberg C

2050

Pfizer Investigational Site, Camperdown

2820

Pfizer Investigational Site, Gentofte Municipality

3081

Pfizer Investigational Site, Heidelberg

4000

Pfizer Investigational Site, Roskilde

4021

Pfizer Investigational Site, Kippa-Ring

5000

Pfizer Investigational Site, Adelaide

5042

Pfizer Investigational Site, Bedford Park

7500

Pfizer Investigational Site, Johannesburg

7708

Pfizer Investigational Site, Cape Town

8000

Pfizer Investigational Site, Aarhus

19104

Pfizer Investigational Site, Philadelphia

27710

Pfizer Investigational Site, Durham

63110

Pfizer Investigational Site, St Louis

70808

Pfizer Investigational Site, Baton Rouge

80220

Pfizer Investigational Site, Denver

92037

Pfizer Investigational Site, La Jolla

98108

Pfizer Investigational Site, Seattle

02118

Pfizer Investigational Site, Boston

10021-7903

Pfizer Investigational Site, New York

1311 RL

Pfizer Investigational Site, Almere Stad

1081 HV

Pfizer Investigational Site, Amsterdam

1105 AZ

Pfizer Investigational Site, Amsterdam

1213 RH

Pfizer Investigational Site, Hilversum

0157

Pfizer Investigational Site, Pretoria

Unknown

Pfizer Investigational Site, Pretoria

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY